Merck adds oncolytics combo study to its huge Keytruda effort

Merck ($MRK) and Houston-based DNAtrix have struck a deal to collaborate on a combination study of the pharma giant's checkpoint inhibitor Keytruda with the biotech's oncolytics immunotherapy DNX-2401. No deal terms were disclosed, but longtime observers will note that Merck R&D chief Roger Perlmutter was an early advocate of oncolytics' potential when he was running the research arm at Amgen ($AMGN) (now pursuing an approval for T-Vec). The oncolytics approach is designed to spur a viral attack that can implode cancer cells while launching an immune system attack. And Perlmutter has maintained a huge commitment to expanding on a pioneering approval for Keytruda. A spokesperson for Merck notes that the company is conducting more than 130 clinical trials for Keytruda across more than 30 tumor types. There are 80 ongoing and planned combo studies. Investigators have been enrolling more than 22,000 patients for the monotherapy and in combination with other therapies. Release

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.